MedPath
HSA Approval

VEELANZ'S OINTMENT

SIN16547P

VEELANZ'S OINTMENT

VEELANZ'S OINTMENT

July 7, 2022

FERRAGOLD SINGAPORE PTE. LTD.

FERRAGOLD SINGAPORE PTE. LTD.

Regulatory Information

FERRAGOLD SINGAPORE PTE. LTD.

FERRAGOLD SINGAPORE PTE. LTD.

Therapeutic

General Sale List

Formulation Information

OINTMENT

**Dosage and Administration** Apply to the affected area morning and evening. Wash the affected area well with warm water before applying the ointment. The treatment should be followed for seven days then discontinued for three days and resumed for further seven days. Continue this pattern of treatment until the condition has cleared up. For treatment of foot itch, the symptoms may disappear only to Re-emerge. Therefore, it is recommended that treatment continue for three weeks after symptoms have disappeared. For treatment of ringworm, it is recommended that treatment continue as long as it is necessary. If the skin problem persists after prolonged treatment, you should consult your doctor.

TOPICAL

Medical Information

**General Indications** For treatment of eczema, itching skin rash, ringworm and foot itch.

**Precautions/contraindications** For external use only. Avoid contact with eyes. In case of contact with eyes, rinse immediately with water. If any irritation occurs, discontinue use. Keep out of reach of children.

D02AF

水杨酸制剂

Manufacturer Information

FERRAGOLD SINGAPORE PTE. LTD.

BEACONS PHARMACEUTICALS PTE. LTD.

Active Ingredients

BENZOIC ACID

6.01% w/w

Benzoic acid

SALICYLIC ACID

2.5% w/w

Salicylic acid

SULPHUR

4.8% w/w

TITANIUM DIOXIDE

10.01% w/w

Titanium dioxide

Documents

Patient Information Leaflets

Leaflet-Veelanz-F-4072022.pdf

Approved: July 7, 2022

Download
© Copyright 2025. All Rights Reserved by MedPath